FDA accepts NDA for UGN-103 in recurrent low-grade intermediate-risk NMIBC
FDA action · CancerNetwork · 2026-10-19. Number 1 in the UrologyWatch Top 5 for October 20, 2026.
The FDA has accepted a new drug application for UGN-103 for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer; a decision is pending.
Why it matters: An approval could add another intravesical option for this NMIBC risk category.
Source: CancerNetwork
Loading today's edition…